The AI-driven platform identifies cell cycle deregulation and tumor immune microenvironment dynamics from biopsy images.

The SERD improved survival endpoints compared to standard adjuvant endocrine therapy in a Phase III trial that may support ...

Although the readout was only from four multiple myeloma patients, attendees at the meeting wondered at how far the CAR T-cell therapy field has come.

Once the exchange agreements close, Sarepta will have $893.4 million in debt due in 2030 following previous refinancing it announced in August.

Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...

At SABCS, Mayo Clinic researchers reported PRS data was more likely to change the risk categories of people with variants in moderate risk penetrance genes.

The firm is testing the EGFR inhibitor BH-30643 in EGFR-mutated NSLC and the CLK inhibitor in certain blood cancers.

Waskyra, developed by Fondazione Telethon, is the first gene therapy that the FDA has approved from a nonprofit applicant.

Patient drug sensitivity profiles were linked to their genomic mutation profiles and could provide prognostic and survival data.

Researchers also discussed access barriers at the meeting, and a survey found distance was a major hindrance to CAR-T ...

Writing in JAMA, regulators said randomized controlled trials with a survival or time-to-event endpoint would be expected for approval of a new CAR T-cell therapy.

An expert panel now recommends using certain personalized therapies in the frontline setting for older adults with FLT3- and IDH1-mutant disease.